Search Results - "Filip, Lardon"

Refine Results
  1. 1

    The potential and controversy of targeting STAT family members in cancer by Verhoeven, Yannick, Tilborghs, Sam, Jacobs, Julie, De Waele, Jorrit, Quatannens, Delphine, Deben, Christophe, Prenen, Hans, Pauwels, Patrick, Trinh, Xuan Bich, Wouters, An, Smits, Evelien L.J., Lardon, Filip, van Dam, Peter A.

    Published in Seminars in cancer biology (01-02-2020)
    “…The Signal Transducer and Activator of Transcription (STAT) family of proteins consists of transcription factors that play a complex and essential role in the…”
    Get full text
    Journal Article
  2. 2

    Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays by Limame, Ridha, Wouters, An, Pauwels, Bea, Fransen, Erik, Peeters, Marc, Lardon, Filip, De Wever, Olivier, Pauwels, Patrick

    Published in PloS one (19-10-2012)
    “…Cell viability and motility comprise ubiquitous mechanisms involved in a variety of (patho)biological processes including cancer. We report a technical…”
    Get full text
    Journal Article
  3. 3

    The CD70-CD27 axis in oncology: the new kids on the block by Flieswasser, Tal, Van den Eynde, Astrid, Van Audenaerde, Jonas, De Waele, Jorrit, Lardon, Filip, Riether, Carsten, de Haard, Hans, Smits, Evelien, Pauwels, Patrick, Jacobs, Julie

    “…The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27…”
    Get full text
    Journal Article
  4. 4

    Cellular senescence in cancer: clinical detection and prognostic implications by Domen, Andreas, Deben, Christophe, Verswyvel, Jasper, Flieswasser, Tal, Prenen, Hans, Peeters, Marc, Lardon, Filip, Wouters, An

    “…Cellular senescence is a state of stable cell-cycle arrest with secretory features in response to cellular stress. Historically, it has been considered as an…”
    Get full text
    Journal Article
  5. 5

    The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies by Baysal, Hasan, De Pauw, Ines, Zaryouh, Hannah, Peeters, Marc, Vermorken, Jan Baptist, Lardon, Filip, De Waele, Jorrit, Wouters, An

    Published in Frontiers in immunology (07-09-2021)
    “…Cetuximab has an established role in the treatment of patients with recurrent/metastatic colorectal cancer and head and neck squamous cell cancer (HNSCC)…”
    Get full text
    Journal Article
  6. 6

    A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy by De Waele, Jorrit, Verhezen, Tias, van der Heijden, Sanne, Berneman, Zwi N, Peeters, Marc, Lardon, Filip, Wouters, An, Smits, Evelien L. J. M

    “…Immunotherapy is currently under intensive investigation as a potential breakthrough treatment option for glioblastoma. Given the anatomical and immunological…”
    Get full text
    Journal Article
  7. 7
  8. 8

    A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy by Deschoolmeester, Vanessa, Baay, Marc, Specenier, Pol, Lardon, Filip, Vermorken, Jan B.

    Published in The oncologist (Dayton, Ohio) (01-07-2010)
    “…Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent developments in gene sequencing and molecular diagnostics have led to…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer by Domen, Andreas, Quatannens, Delphine, Zanivan, Sara, Deben, Christophe, Van Audenaerde, Jonas, Smits, Evelien, Wouters, An, Lardon, Filip, Roeyen, Geert, Verhoeven, Yannick, Janssens, Annelies, Vandamme, Timon, van Dam, Peter, Peeters, Marc, Prenen, Hans

    Published in Cancers (27-02-2021)
    “…Cancer arises from mutations accruing within cancer cells, but the tumor microenvironment (TME) is believed to be a major, often neglected, factor involved in…”
    Get full text
    Journal Article
  11. 11

    Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients by Deschoolmeester, Vanessa, Baay, Marc, Van Marck, Eric, Weyler, Joost, Vermeulen, Peter, Lardon, Filip, Vermorken, Jan B

    Published in BMC immunology (12-04-2010)
    “…There is growing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of solid tumors…”
    Get full text
    Journal Article
  12. 12

    Immune Checkpoint Modulation in Colorectal Cancer: What’s New and What to Expect by Pauwels, Patrick, Lardon, Filip, Smits, Evelien, Jacobs, Julie, Deschoolmeester, Vanessa

    Published in Journal of immunology research (01-01-2015)
    “…Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need…”
    Get full text
    Journal Article
  13. 13

    Anti‐Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance by Boeckx, Carolien, Baay, Marc, Wouters, An, Specenier, Pol, Vermorken, Jan B., Peeters, Marc, Lardon, Filip

    Published in The oncologist (Dayton, Ohio) (01-07-2013)
    “…Targeted therapy against the epidermal growth factor receptor (EGFR) is one of the most promising molecular therapeutics for head and neck squamous cell…”
    Get full text
    Journal Article
  14. 14

    The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy by Zaryouh, Hannah, De Pauw, Ines, Baysal, Hasan, Pauwels, Patrick, Peeters, Marc, Vermorken, Jan Baptist, Lardon, Filip, Wouters, An

    Published in Frontiers in oncology (10-09-2021)
    “…The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies,…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer by Flieswasser, Tal, Van den Eynde, Astrid, Freire Boullosa, Laurie, Melis, Jöran, Hermans, Christophe, Merlin, Céline, Lau, Ho Wa, Van Audenaerde, Jonas, Lardon, Filip, Smits, Evelien, Pauwels, Patrick, Jacobs, Julie

    Published in Oncoimmunology (31-12-2023)
    “…Despite the recent emergence of immune checkpoint inhibitors, clinical outcomes of metastatic NSCLC patients remain poor, pointing out the unmet need to…”
    Get full text
    Journal Article
  18. 18

    The prognostic impact of the immune signature in head and neck squamous cell carcinoma by Baysal, Hasan, Siozopoulou, Vasiliki, Zaryouh, Hannah, Hermans, Christophe, Lau, Ho Wa, Lambrechts, Hilde, Fransen, Erik, De Pauw, Ines, Jacobs, Julie, Peeters, Marc, Pauwels, Patrick, Vermorken, Jan Baptist, Smits, Evelien, Lardon, Filip, De Waele, Jorrit, Wouters, An

    Published in Frontiers in immunology (04-10-2022)
    “…Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that retain their poor prognosis despite recent advances in their standard of…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update by Verhoeven, Yannick, Quatannens, Delphine, Trinh, Xuan Bich, Wouters, An, Smits, Evelien L J, Lardon, Filip, De Waele, Jorrit, van Dam, Peter A

    “…Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved…”
    Get full text
    Journal Article